1-50 of 7,532 results for subject:Genetics
Librarians' tools
- Search time
- 0.317 seconds
- Solr query time
- 0.017 seconds
- Search query
- subject:Genetics
- We searched for
- subject_t:Genetics OR subject_t:"Genetic fingerprinting" OR subject_t:"Genetic fingerprints" OR subject_ses:91417
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what plans he has to improve transparency on uptake, turnaround times and outcomes for genetic and biomarker testing across the NHS.
To ask the Secretary of State for Health and Social Care, what plans he has to improve transparency on uptake, turnaround times and outcomes for genetic and biomarker testing across the NHS.
HS England is responsible for commissioning the NHS Genomic Medicine Service (GMS). Genomic testing in the National Health Service in England is provided through the NHS GMS and the genomic testing nationally commissioned and funded by NHS England for patients in England is set out in the National Genomic Test Directory.
NHS England captures Patient Level Contract Monitoring (PLCM) data across the NHS GMS to facilitate a national approach to reporting and validating activity data and turnaround times for the genomics element of the pathway. NHS England holds quarterly assurance meetings with the NHS GMS to oversee delivery and publishes PLCM data on a quarterly basis on the NHS England website, at the following link:
https://www.england.nhs.uk/statistics/statistical-work-areas/genomic-testing-activity/
NHS England continues to develop this dataset, and in the future will develop the collecting and reporting of outcome data.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 July 2026 to Question 11285, and with reference to the report entitled UK National Screening Committee, Screening for prostate cancer, whether his Department is taking steps to estimate the cost of identifying new...
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 July 2026 to Question 11285, and with reference to the report entitled UK National Screening Committee, Screening for prostate cancer, whether his Department is taking steps to estimate the cost of identifying new...
The Department estimates that there are approximately 1,500 men currently known to have both a BRCA2 gene variant and a family history of breast, pancreatic, ovarian, or prostate cancer who will be eligible for the targeted prostate cancer screening programme. The Department has not estimated the costs of identifying additional BRCA2 variant carriers, as the UK National Screening Committee, which advises the Government on all screening related matters, did not recommend proactively identifying BRCA2 carriers.
That this House marks the 30th anniversary of the birth of Dolly the Sheep on 5 July 1996 at the Roslin Institute in Midlothian, the first mammal to be successfully cloned from an adult somatic cell; recognises that Dolly's birth was a landmark scientific achievement which transformed understanding of developmental biology and helped pave the way for major advances in regenerative medicine, stem cell science and biotechnology; commends the pioneering work of Professor Sir Ian Wilmut, Keith Campbell and their colleagues at the Roslin Institute and PPL Therapeutics; notes the significant contribution that the Roslin Institute, the University of Edinburgh and Scotland's world-leading life sciences sector have made to scientific innovation and economic growth; further notes the successful development of companies arising from Roslin's research and innovation ecosystem, including RoslinCT, a leading cell and gene therapy development and manufacturing company established as a Roslin spin-out in 2006, and Roslin Technologies, founded in 2017 to commercialise advanced animal stem-cell technologies and support sustainable food production and animal health innovation; acknowledges the wider impact of Roslin-linked commercial ventures and knowledge transfer activities in creating highly skilled employment and attracting investment to Scotland; and celebrates Dolly's enduring legacy as a symbol of Scottish scientific excellence and global innovation.
That this House marks the 30th anniversary of the birth of Dolly the Sheep on 5 July 1996 at the Roslin Institute in Midlothian, the first mammal to be successfully cloned from an adult somatic cell; recognises that Dolly's birth was a landmark scientific achievement which transformed understanding of developmental...
To ask the Secretary of State for Health and Social Care, what steps the Department is taking to improve interoperability between rare-disease registries and genomic-data systems across the UK.
To ask the Secretary of State for Health and Social Care, what steps the Department is taking to improve interoperability between rare-disease registries and genomic-data systems across the UK.
The Government is committed to ensuring that all patients across the UK have access to cutting-edge clinical trials and innovative, lifesaving treatments, and we are working with the devolved administrations, delivery partners across the health system, and key stakeholders from across the clinical research sector – all under the umbrella of the UK Clinical Research Delivery Programme (UKCRD) – to increase commercial research participation, and make the UK a world leader in clinical trials.
To increase participation by patients across all four nations, we are establishing 21 new Commercial Research Delivery Centres (CRDCs) across the UK, alongside a UK-wide CRDC Network, which will coordinate activity, provide strategic leadership, and support consistency across the centres. The CRDC Network complements established UK-wide infrastructure, including the Experimental Cancer Medicine Centres Network and the UK Clinical Research Facility Network, which support research delivery, strengthen capability, and enable patients across England, Scotland, Wales, and Northern Ireland to access innovative clinical trials.
The Hon Member may also be aware that the National Institute for Health and Care Research provides a UK-wide online service called Be Part of Research, which promotes participation in health and social care research by allowing users to search for relevant studies and register their interest. This makes it easier for people across the UK to find and take part in commercial clinical trials and other health and care research.
In addition to the activity set out above, the Government is taking specific action through the UK Rare Diseases Framework to improve the lives of people living with rare diseases, and last year extended the framework to continue until 2027. The framework sets out four shared priorities for addressing rare diseases across England, Scotland, Wales and Northern Ireland: improving speed of diagnosis; raising awareness of rare conditions with healthcare professionals; coordinating care; and providing access to specialist care and treatments.
Genomic testing and analysis of genomic data is at the heart of the UK Rare Diseases Framework, and the agencies contributing to that activity are taking constant steps to increase interoperability between rare disease registries, genomic data systems, and clinical records held across the four nations, to assist in research, testing and analysis.
I would like to raise a deeply troubling case that highlights serious concerns about the integrity of DNA testing within the Child Maintenance Service and questions surrounding the existing safeguards in place to protect families.
I want to share, as was recounted to me, what happened to my constituent Ms Chelsea...
I would like to raise a deeply troubling case that highlights serious concerns about the integrity of DNA testing within the Child Maintenance Service and questions surrounding the existing safeguards in place to protect families.
I want to share, as was recounted to me, what happened to my constituent Ms Chelsea...
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of additional men expected to be eligible for prostate cancer screening each year under the UK National Screening Committee’s recommended criteria, when taking into account those men already known to genetic...
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of additional men expected to be eligible for prostate cancer screening each year under the UK National Screening Committee’s recommended criteria, when taking into account those men already known to genetic...
The UK National Screening recommendation was for a targeted screening programme, involving prostate-specific antigen testing every two years, for men aged 45 to 61 years old who have a pathogenic, or able to cause disease, BRCA2 variant with a family history of breast, ovarian, pancreatic, or prostate cancer.
It is estimated that approximately 1,500 men in England will be eligible for the targeted prostate cancer screening programme. Based on similar programmes for people with genetic risk factors, uptake is expected to be high.
The intention is to use the National Inherited Cancer Predisposition Register (NICPR), to identify men with a known BRCA2 gene variant. Individuals are added to the NICPR as their gene variants are identified, and this is usually through cascade screening or as the result of having cancer and their tumour being genotyped. No estimate has been made of the additional numbers that may be identified using this method.
The Department is not undertaking analysis of the costs associated with identifying additional BRCA variant carriers. The committee did not recommend proactively identifying more men with a BRCA variant, as this would constitute a separate screening programme. The committee recommended that the best method of identifying men with a BRCA2 gene variant should be evaluated over time.
To ask the Secretary of State for Health and Social Care, when he expects the Department’s analysis of the costs associated with identifying additional BRCA variant carriers to be completed.
To ask the Secretary of State for Health and Social Care, when he expects the Department’s analysis of the costs associated with identifying additional BRCA variant carriers to be completed.
The UK National Screening recommendation was for a targeted screening programme, involving prostate-specific antigen testing every two years, for men aged 45 to 61 years old who have a pathogenic, or able to cause disease, BRCA2 variant with a family history of breast, ovarian, pancreatic, or prostate cancer.
It is estimated that approximately 1,500 men in England will be eligible for the targeted prostate cancer screening programme. Based on similar programmes for people with genetic risk factors, uptake is expected to be high.
The intention is to use the National Inherited Cancer Predisposition Register (NICPR), to identify men with a known BRCA2 gene variant. Individuals are added to the NICPR as their gene variants are identified, and this is usually through cascade screening or as the result of having cancer and their tumour being genotyped. No estimate has been made of the additional numbers that may be identified using this method.
The Department is not undertaking analysis of the costs associated with identifying additional BRCA variant carriers. The committee did not recommend proactively identifying more men with a BRCA variant, as this would constitute a separate screening programme. The committee recommended that the best method of identifying men with a BRCA2 gene variant should be evaluated over time.
To ask the Secretary of State for Health and Social Care, if he will set out how his Department will roll out breast cancer gene (BRCA) testing nationally.
To ask the Secretary of State for Health and Social Care, if he will set out how his Department will roll out breast cancer gene (BRCA) testing nationally.
Genomic testing in the National Health Service in England is provided through the NHS Genomic Medicine Service and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory, which includes tests for over 7,000 rare diseases with an associated genetic cause and over 200 cancer clinical indications, including testing for genetic predisposition conditions. Further information on the National Genomic Test Directory is available at the following link:
https://www.england.nhs.uk/publication/national-genomic-test-directories/
Genomic testing is available for all eligible patients across the whole of England. Individuals should discuss with their healthcare professional whether genomic testing is appropriate for them. Their healthcare professional will then make a decision whether to refer the individual either directly or via an NHS Clinical Genomics Service or other relevant clinical speciality for genomic testing following clinical review of their and their family’s medical history if known, and the relevant genomic testing eligibility criteria.
Testing for inherited breast and ovarian cancer, where there is a living unaffected individual, is covered in the National Genomic Test Directory under clinical indication R208.
The current eligibility criteria include unaffected individuals who have a first-degree relative with breast cancer or high-grade serous ovarian cancer, where the individual or affected relative meets the relevant risk threshold. Testing is available where no living affected relative is available for genetic testing and no tumour material is available from a deceased affected relative.
The NHS England Genomics Programme and Cancer Programme has also, in recent years, supported the NHS Jewish BRCA Testing Programme, a three-year pilot programme to offer testing to individuals living in England, aged 18 years old or over with at least one Jewish grandparent, regardless of faith, religious practice, or any other criteria.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of a proactive approach to offering breast cancer gene (BRCA) testing to those who have lost a family member to ovarian or breast cancer.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of a proactive approach to offering breast cancer gene (BRCA) testing to those who have lost a family member to ovarian or breast cancer.
Genomic testing in the National Health Service in England is provided through the NHS Genomic Medicine Service and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory, which includes tests for over 7,000 rare diseases with an associated genetic cause and over 200 cancer clinical indications, including testing for genetic predisposition conditions. Further information on the National Genomic Test Directory is available at the following link:
https://www.england.nhs.uk/publication/national-genomic-test-directories/
Genomic testing is available for all eligible patients across the whole of England. Individuals should discuss with their healthcare professional whether genomic testing is appropriate for them. Their healthcare professional will then make a decision whether to refer the individual either directly or via an NHS Clinical Genomics Service or other relevant clinical speciality for genomic testing following clinical review of their and their family’s medical history if known, and the relevant genomic testing eligibility criteria.
Testing for inherited breast and ovarian cancer, where there is a living unaffected individual, is covered in the National Genomic Test Directory under clinical indication R208.
The current eligibility criteria include unaffected individuals who have a first-degree relative with breast cancer or high-grade serous ovarian cancer, where the individual or affected relative meets the relevant risk threshold. Testing is available where no living affected relative is available for genetic testing and no tumour material is available from a deceased affected relative.
The NHS England Genomics Programme and Cancer Programme has also, in recent years, supported the NHS Jewish BRCA Testing Programme, a three-year pilot programme to offer testing to individuals living in England, aged 18 years old or over with at least one Jewish grandparent, regardless of faith, religious practice, or any other criteria.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) define populations with high risk of carrying harmful breast cancer (BRCA) gene variants and (b) increase testing levels amongst those communities.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) define populations with high risk of carrying harmful breast cancer (BRCA) gene variants and (b) increase testing levels amongst those communities.
Genomic testing in the National Health Service in England is provided through the NHS Genomic Medicine Service and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory, which includes tests for over 7,000 rare diseases with an associated genetic cause and over 200 cancer clinical indications, including testing for genetic predisposition conditions. Further information on the National Genomic Test Directory is available at the following link:
https://www.england.nhs.uk/publication/national-genomic-test-directories/
Genomic testing is available for all eligible patients across the whole of England. Individuals should discuss with their healthcare professional whether genomic testing is appropriate for them. Their healthcare professional will then make a decision whether to refer the individual either directly or via an NHS Clinical Genomics Service or other relevant clinical speciality for genomic testing following clinical review of their and their family’s medical history if known, and the relevant genomic testing eligibility criteria.
Testing for inherited breast and ovarian cancer, where there is a living unaffected individual, is covered in the National Genomic Test Directory under clinical indication R208.
The current eligibility criteria include unaffected individuals who have a first-degree relative with breast cancer or high-grade serous ovarian cancer, where the individual or affected relative meets the relevant risk threshold. Testing is available where no living affected relative is available for genetic testing and no tumour material is available from a deceased affected relative.
The NHS England Genomics Programme and Cancer Programme has also, in recent years, supported the NHS Jewish BRCA Testing Programme, a three-year pilot programme to offer testing to individuals living in England, aged 18 years old or over with at least one Jewish grandparent, regardless of faith, religious practice, or any other criteria.
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 30 March (HL15661), whether the National Cancer Plan commitment that every cancer patient who needs a genomic test will receive one also applies to non-genomic tests required to guide precision treatment.
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 30 March (HL15661), whether the National Cancer Plan commitment that every cancer patient who needs a genomic test will receive one also applies to non-genomic tests required to guide precision treatment.
The National Cancer Plan commitment for all cancer patients who would benefit from a genomic test to receive one to inform treatment decisions applies specifically to genomic testing. While the Plan supports the wider use of biomarker testing, including non-genomic tests, these are being expanded and integrated across cancer pathways rather than subject to a similar universal guarantee.
The Plan commits to the wider integration of biomarker testing across cancer services to improve treatment selection and outcomes. Non-genomic biomarker tests form part of wider diagnostic pathways, alongside histopathology, imaging such as magnetic resonance imaging and computed tomography scans, and other laboratory investigations, all of which contribute to multidisciplinary team decisions on the most appropriate treatment.
Through the National Cancer Plan, more equitable access to precision cancer treatments will be supported by reducing unwarranted variation, reviewing the scope of testing, and bringing additional biomarker tests, both genomic and non-genomic, into routine use where clinically appropriate. This will be supported by national guidance and commissioning processes to ensure consistent access across the National Health Service.
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 30 March (HL15661), what assessment they have made of the impact on equitable access to precision cancer treatments if non-genomic biomarker testing is not guaranteed for all patients who require it.
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 30 March (HL15661), what assessment they have made of the impact on equitable access to precision cancer treatments if non-genomic biomarker testing is not guaranteed for all patients who require it.
The National Cancer Plan commitment for all cancer patients who would benefit from a genomic test to receive one to inform treatment decisions applies specifically to genomic testing. While the Plan supports the wider use of biomarker testing, including non-genomic tests, these are being expanded and integrated across cancer pathways rather than subject to a similar universal guarantee.
The Plan commits to the wider integration of biomarker testing across cancer services to improve treatment selection and outcomes. Non-genomic biomarker tests form part of wider diagnostic pathways, alongside histopathology, imaging such as magnetic resonance imaging and computed tomography scans, and other laboratory investigations, all of which contribute to multidisciplinary team decisions on the most appropriate treatment.
Through the National Cancer Plan, more equitable access to precision cancer treatments will be supported by reducing unwarranted variation, reviewing the scope of testing, and bringing additional biomarker tests, both genomic and non-genomic, into routine use where clinically appropriate. This will be supported by national guidance and commissioning processes to ensure consistent access across the National Health Service.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the potential cost savings to the NHS from earlier identification of BRCA1 mutations through expanded screening.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the potential cost savings to the NHS from earlier identification of BRCA1 mutations through expanded screening.
The current eligibility criteria for genetic testing are set out in the NHS National Genomic Test Directory. The aim is to offer individuals at higher risk of developing cancer (those with pathogenic variants in their genes) clinical pathways to support them to manage their risk, offer their family members testing and ultimately lead to more cancers being prevented or detected earlier. The directory is available at the following link:
https://www.england.nhs.uk/publication/national-genomic-test-directories/
NHS England is currently funding the Retrospective Genetic Testing Programme to offer genetic testing to people who have not yet received a test, in line with the current eligibility criteria set out in the directory. More information is available at the following link:
https://brca-direct.icr.ac.uk/privacy_policy
All individuals who test positive will be added to the National Inherited Cancer Predisposition Register. More information is available at the following link:
https://digital.nhs.uk/ndrs/our-work/genomics/nicpr
Following this, individuals will be invited for screening in line with guidance available at the following link:
The UK National Screening Committee has not been asked to consider whether a screening programme for BRCA1 would be appropriate for women with a family history of breast or ovarian cancer, and no cost effectiveness estimates have been made of such a policy.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of recommending screening for the BRCA 1 gene for women who have a mother who has died from (a) breast and (b) ovarian cancers.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of recommending screening for the BRCA 1 gene for women who have a mother who has died from (a) breast and (b) ovarian cancers.
The current eligibility criteria for genetic testing are set out in the NHS National Genomic Test Directory. The aim is to offer individuals at higher risk of developing cancer (those with pathogenic variants in their genes) clinical pathways to support them to manage their risk, offer their family members testing and ultimately lead to more cancers being prevented or detected earlier. The directory is available at the following link:
https://www.england.nhs.uk/publication/national-genomic-test-directories/
NHS England is currently funding the Retrospective Genetic Testing Programme to offer genetic testing to people who have not yet received a test, in line with the current eligibility criteria set out in the directory. More information is available at the following link:
https://brca-direct.icr.ac.uk/privacy_policy
All individuals who test positive will be added to the National Inherited Cancer Predisposition Register. More information is available at the following link:
https://digital.nhs.uk/ndrs/our-work/genomics/nicpr
Following this, individuals will be invited for screening in line with guidance available at the following link:
The UK National Screening Committee has not been asked to consider whether a screening programme for BRCA1 would be appropriate for women with a family history of breast or ovarian cancer, and no cost effectiveness estimates have been made of such a policy.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of NHS eligibility criteria for BRCA1 genetic testing for individuals with a family history of (a) breast and (b) ovarian cancer.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of NHS eligibility criteria for BRCA1 genetic testing for individuals with a family history of (a) breast and (b) ovarian cancer.
The current eligibility criteria for genetic testing are set out in the NHS National Genomic Test Directory. The aim is to offer individuals at higher risk of developing cancer (those with pathogenic variants in their genes) clinical pathways to support them to manage their risk, offer their family members testing and ultimately lead to more cancers being prevented or detected earlier. The directory is available at the following link:
https://www.england.nhs.uk/publication/national-genomic-test-directories/
NHS England is currently funding the Retrospective Genetic Testing Programme to offer genetic testing to people who have not yet received a test, in line with the current eligibility criteria set out in the directory. More information is available at the following link:
https://brca-direct.icr.ac.uk/privacy_policy
All individuals who test positive will be added to the National Inherited Cancer Predisposition Register. More information is available at the following link:
https://digital.nhs.uk/ndrs/our-work/genomics/nicpr
Following this, individuals will be invited for screening in line with guidance available at the following link:
The UK National Screening Committee has not been asked to consider whether a screening programme for BRCA1 would be appropriate for women with a family history of breast or ovarian cancer, and no cost effectiveness estimates have been made of such a policy.
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 30 March (HL15661), whether the National Cancer Plan commitment that every cancer patient who needs a genomic test will receive one also applies to non-genomic tests required to guide precision treatment.
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 30 March (HL15661), whether the National Cancer Plan commitment that every cancer patient who needs a genomic test will receive one also applies to non-genomic tests required to guide precision treatment.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the impact that greater histopathology capacity would have on delivering the Government’s ambition to provide comprehensive molecular profiling to every eligible cancer patient.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the impact that greater histopathology capacity would have on delivering the Government’s ambition to provide comprehensive molecular profiling to every eligible cancer patient.
The Department recognises the vital role that histopathology services play in supporting timely diagnosis and access to advanced pathology testing, including molecular profiling where clinically appropriate. These services underpin cancer pathways and enable more personalised treatments, while also supporting the diagnosis, monitoring, and treatment of a wide range of non-cancer conditions.
To support the expansion of high-quality histopathology capacity, we will deliver significant investment in laboratory modernisation, including a £96 million investment to automate histopathology. This investment will aim to speed up the processing and reporting of tissue samples and enable the National Health Service to meet the 98% standard for results to be reported in 10 days by March 2029. Delivering these improvements will enable the Department to meet our commitment of providing comprehensive molecular profiling of all cancers, which will help to inform risk stratification and support the use of more precise, targeted medicines earlier in the treatment pathway.
To ask the Secretary of State for Health and Social Care, what consideration his Department has given to reviewing NHS optical voucher values for children with complex visual needs, particularly those with conditions such as Albanism.
To ask the Secretary of State for Health and Social Care, what consideration his Department has given to reviewing NHS optical voucher values for children with complex visual needs, particularly those with conditions such as Albanism.
The Government recognises the importance of ensuring that children, including those with complex visual needs such as albinism, can access appropriate optical care and appliances.
National Health Service optical vouchers are designed to support eligible groups, including children, with the cost of clinically necessary glasses or contact lenses. Voucher values range from £42.40 to £233.56, with individuals with more complex prescriptions receiving the high voucher values. There are no plans for a review of NHS optical vouchers.
Children and young people with significant or complex vision impairment may also be supported through NHS low vision services. These services provide specialist assessment and, where appropriate, low vision aids to help maximise functional vision and independence.
Is it possible for the noble Lord to speak a bit louder? We old, deaf people back here find it quite hard to hear him.
Is it possible for the noble Lord to speak a bit louder? We old, deaf people back here find it quite hard to hear him.
It is because of the speaker system.
It is because of the speaker system.
Okay, maybe he can shout a bit.
Okay, maybe he can shout a bit.
Can everyone hear me now? Can the noble Baroness, Lady Bottomley, hear?
Can everyone hear me now? Can the noble Baroness, Lady Bottomley, hear?
Yes.
Yes.
Thank you. One in two people in the United Kingdom will develop cancer. Being born with cancer is rare, but a new cancer diagnosis is made every 75 seconds. The UK consistently ranks near the bottom of the table for survivals and deaths from cancers. That is despite several cancer...
Thank you. One in two people in the United Kingdom will develop cancer. Being born with cancer is rare, but a new cancer diagnosis is made every 75 seconds. The UK consistently ranks near the bottom of the table for survivals and deaths from cancers. That is despite several cancer...
My Lords, I thank the noble Lord, Lord Patel, for securing the debate and pay tribute to his indefatigable commitment to improving health outcomes and championing research and to his powerful and moving speech. I am pleased to have the opportunity to contribute to the debate. I know that I...
My Lords, I thank the noble Lord, Lord Patel, for securing the debate and pay tribute to his indefatigable commitment to improving health outcomes and championing research and to his powerful and moving speech. I am pleased to have the opportunity to contribute to the debate. I know that I...
My Lords, I, too, most warmly congratulate the noble Lord on securing this debate. I always think health matters should be handled by a former president of a royal college, and it is excellent that we have another former president of a royal college with us today. This should be...
My Lords, I, too, most warmly congratulate the noble Lord on securing this debate. I always think health matters should be handled by a former president of a royal college, and it is excellent that we have another former president of a royal college with us today. This should be...
My Lords, I congratulate my noble friend Lord Patel on securing this important debate, to which it is a pleasure to contribute. I declare my interest as a fellow of the Royal College of Nursing, and I am delighted that I will be followed by a previous president of the...
My Lords, I congratulate my noble friend Lord Patel on securing this important debate, to which it is a pleasure to contribute. I declare my interest as a fellow of the Royal College of Nursing, and I am delighted that I will be followed by a previous president of the...
My Lords, it is a pleasure to follow the noble Baroness, Lady Watkins, a fellow nurse. I add my congratulations to the noble Lord, Lord Patel, on securing such a timely debate. There is a lot to commend in the National Cancer Plan for England, but, speaking as a nurse...
My Lords, it is a pleasure to follow the noble Baroness, Lady Watkins, a fellow nurse. I add my congratulations to the noble Lord, Lord Patel, on securing such a timely debate. There is a lot to commend in the National Cancer Plan for England, but, speaking as a nurse...
My Lords, I, too, thank the noble Lord, Lord Patel, for securing this debate and for introducing it so powerfully in his usual inimitable fashion. I declare my interests as a trustee of the Royal Marsden Cancer Charity, as a former patient and as someone married to a current patient.
We...
My Lords, I, too, thank the noble Lord, Lord Patel, for securing this debate and for introducing it so powerfully in his usual inimitable fashion. I declare my interests as a trustee of the Royal Marsden Cancer Charity, as a former patient and as someone married to a current patient.
We...
My Lords, I thank the noble Lord, Lord Patel, for securing this important debate and for his excellent introduction. I declare my interest as the founder and a trustee of Health Equality Foundation, a UK national charity.
I welcome the Government’s National Cancer Plan for England and pay tribute to the...
My Lords, I thank the noble Lord, Lord Patel, for securing this important debate and for his excellent introduction. I declare my interest as the founder and a trustee of Health Equality Foundation, a UK national charity.
I welcome the Government’s National Cancer Plan for England and pay tribute to the...
My Lords, I join other noble Lords in congratulating and thanking my noble friend Lord Patel for having secured this important debate and having introduced it, as he always does, in such a thoughtful and sensitive fashion. In so doing, I remind noble Lords of my own interests as the...
My Lords, I join other noble Lords in congratulating and thanking my noble friend Lord Patel for having secured this important debate and having introduced it, as he always does, in such a thoughtful and sensitive fashion. In so doing, I remind noble Lords of my own interests as the...
My Lords, it is a privilege to follow the noble Lord, Lord Kakkar, and to contribute to this debate on the National Cancer Plan. I thank my colleague on the Science and Technology Committee, the noble Lord, Lord Patel. I draw the Committee’s attention to my declared interests in the...
My Lords, it is a privilege to follow the noble Lord, Lord Kakkar, and to contribute to this debate on the National Cancer Plan. I thank my colleague on the Science and Technology Committee, the noble Lord, Lord Patel. I draw the Committee’s attention to my declared interests in the...
My Lords, I also thank the noble Lord, Lord Patel, for securing this timely debate. One of the lessons of history is that, so often, we fail to learn the lessons of history. I say this particularly in relation to prostate cancer. It is the most diagnosed cancer in men...
My Lords, I also thank the noble Lord, Lord Patel, for securing this timely debate. One of the lessons of history is that, so often, we fail to learn the lessons of history. I say this particularly in relation to prostate cancer. It is the most diagnosed cancer in men...
My Lords, it is a privilege to have the opportunity to contribute to this important debate regarding improving cancer outcomes and diagnostic care and research. I congratulate the noble Lord, Lord Patel, on securing it.
I shall first concentrate on the importance of early diagnosis, which, as we are all aware,...
My Lords, it is a privilege to have the opportunity to contribute to this important debate regarding improving cancer outcomes and diagnostic care and research. I congratulate the noble Lord, Lord Patel, on securing it.
I shall first concentrate on the importance of early diagnosis, which, as we are all aware,...
My Lords, like others I am most grateful to my noble friend Lord Patel for securing this debate today, which is acute myeloid leukaemia day—so it seems very appropriate. I declare my interests as a professor of palliative medicine at Cardiff University and am employed at Velindre cancer centre, as...
My Lords, like others I am most grateful to my noble friend Lord Patel for securing this debate today, which is acute myeloid leukaemia day—so it seems very appropriate. I declare my interests as a professor of palliative medicine at Cardiff University and am employed at Velindre cancer centre, as...
My Lords, I too congratulate the noble Lord, Lord Patel, on securing this important debate. I declare my interest as a member of the General Medical Council.
Like many other noble Lords, my interest in this very important subject is personal. My father and older sister both died of lung cancer....
My Lords, I too congratulate the noble Lord, Lord Patel, on securing this important debate. I declare my interest as a member of the General Medical Council.
Like many other noble Lords, my interest in this very important subject is personal. My father and older sister both died of lung cancer....
My Lords, I pile on to the congratulations to the noble Lord, Lord Patel, on this fantastic session. Given the excellence of the contributions that we have already heard, I will just draw out a small number of things. I will try not to be duplicative of the brilliant contributions...
My Lords, I pile on to the congratulations to the noble Lord, Lord Patel, on this fantastic session. Given the excellence of the contributions that we have already heard, I will just draw out a small number of things. I will try not to be duplicative of the brilliant contributions...
My Lords, like many before me, I thank my noble friend Lord Patel for securing this debate and other noble Lords for the excellent contributions that have been made so far. I beg your Lordships’ indulgence—my comments are of a more personal nature than some of the others we have...
My Lords, like many before me, I thank my noble friend Lord Patel for securing this debate and other noble Lords for the excellent contributions that have been made so far. I beg your Lordships’ indulgence—my comments are of a more personal nature than some of the others we have...
My Lords, I thank the noble Lord, Lord Patel, for securing this important debate. When I was a Minister, the noble Lord used to stand up and ask me extremely searching questions—well, they were searching questions to me—to which I did not always know the answer. Come to think of...
My Lords, I thank the noble Lord, Lord Patel, for securing this important debate. When I was a Minister, the noble Lord used to stand up and ask me extremely searching questions—well, they were searching questions to me—to which I did not always know the answer. Come to think of...
My Lords, I am grateful to contribute to this debate, and I too thank the noble Lord, Lord Patel. I declare my interest: I am a practising GP just across the river, and, over the past 40 years, I have diagnosed and cared for many tens of thousands of patients...
My Lords, I am grateful to contribute to this debate, and I too thank the noble Lord, Lord Patel. I declare my interest: I am a practising GP just across the river, and, over the past 40 years, I have diagnosed and cared for many tens of thousands of patients...
My Lords, it is a pleasure to follow the noble Baroness, Lady Gerada. I congratulate my noble friend Lord Patel on securing this important debate, which places emphasis on diagnostic care, research and the necessary delivery mechanisms to implement the National Cancer Plan.
I am a breast cancer survivor who was...
My Lords, it is a pleasure to follow the noble Baroness, Lady Gerada. I congratulate my noble friend Lord Patel on securing this important debate, which places emphasis on diagnostic care, research and the necessary delivery mechanisms to implement the National Cancer Plan.
I am a breast cancer survivor who was...
My Lords, I am very grateful to the noble Lord, Lord Patel, for giving us the opportunity to talk about cancer today, because I am a very lucky woman: like the noble Baroness, Lady Ritchie, I am a cancer survivor. My cancer was picked up by routine screening, so I...
My Lords, I am very grateful to the noble Lord, Lord Patel, for giving us the opportunity to talk about cancer today, because I am a very lucky woman: like the noble Baroness, Lady Ritchie, I am a cancer survivor. My cancer was picked up by routine screening, so I...
My Lords, I declare my interest as an honorary fellow of the Royal College of Physicians. If I have learned one thing during my time in the House of Lords, it is that any pronouncement emanating from the lips of the noble Lord, Lord Patel, should be listened to with...
My Lords, I declare my interest as an honorary fellow of the Royal College of Physicians. If I have learned one thing during my time in the House of Lords, it is that any pronouncement emanating from the lips of the noble Lord, Lord Patel, should be listened to with...
My Lords, I congratulate the noble Lord, Lord Patel, on securing this excellent debate. I thank him for bringing his considerable expertise and careful consideration—as he always does, as other noble Lords have said—to these matters. He has assembled a pretty daunting selection of noble Lords, for which I am...
My Lords, I congratulate the noble Lord, Lord Patel, on securing this excellent debate. I thank him for bringing his considerable expertise and careful consideration—as he always does, as other noble Lords have said—to these matters. He has assembled a pretty daunting selection of noble Lords, for which I am...
My Lords, I thank the Minister for her comprehensive response. She might reflect on some of the other points that she was not able to answer, such as the one on isotopes, which is very important. We have debated that before. One or two noble Lords quite rightly mentioned children’s...
My Lords, I thank the Minister for her comprehensive response. She might reflect on some of the other points that she was not able to answer, such as the one on isotopes, which is very important. We have debated that before. One or two noble Lords quite rightly mentioned children’s...
Lords motion to take note of cancer outcomes in the UK and of plans to improve them including diagnostic care and research. Agreed to on question.
Lords motion to take note of cancer outcomes in the UK and of plans to improve them including diagnostic care and research. Agreed to on question.
My Lords, sitting on the same side as the Minister does not mean that I am on her side. I thank all noble Lords taking part in the debate and look forward to their contributions. There is a formidable array of talent, so the Minister should get a good response....
My Lords, sitting on the same side as the Minister does not mean that I am on her side. I thank all noble Lords taking part in the debate and look forward to their contributions. There is a formidable array of talent, so the Minister should get a good response....